Legis Daily

Cameron’s Law

USA117th CongressHR-2623| House 
| Updated: 4/19/2021
Josh Gottheimer

Josh Gottheimer

Democratic Representative

New Jersey

Cosponsors (2)
Don Bacon (Republican)Fred Upton (Republican)

Ways and Means Committee, Health Subcommittee, Energy and Commerce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Cameron's Law This bill increases the rate of the tax credit for clinical testing expenses for rare diseases or conditions from 25% to 50% (orphan drug tax credit). The bill also requires the Centers for Disease Control and Prevention to complete a study to evaluate the feasibility of enhancing and expanding the infrastructure to track the epidemiology of rare diseases or conditions.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

HR 116-6238
Cameron’s Law
Apr 16, 2021
Introduced in House
Apr 16, 2021
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 19, 2021
Referred to the Subcommittee on Health.
  • Bill from Previous Congress

    HR 116-6238
    Cameron’s Law


  • April 16, 2021
    Introduced in House


  • April 16, 2021
    Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.


  • April 19, 2021
    Referred to the Subcommittee on Health.

Taxation

Business expensesCongressional oversightDrug safety, medical device, and laboratory regulationDrug therapyGovernment studies and investigationsIncome tax creditsMedical researchMedical tests and diagnostic methodsResearch and development

Cameron’s Law

USA117th CongressHR-2623| House 
| Updated: 4/19/2021
Cameron's Law This bill increases the rate of the tax credit for clinical testing expenses for rare diseases or conditions from 25% to 50% (orphan drug tax credit). The bill also requires the Centers for Disease Control and Prevention to complete a study to evaluate the feasibility of enhancing and expanding the infrastructure to track the epidemiology of rare diseases or conditions.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

HR 116-6238
Cameron’s Law
Apr 16, 2021
Introduced in House
Apr 16, 2021
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 19, 2021
Referred to the Subcommittee on Health.
  • Bill from Previous Congress

    HR 116-6238
    Cameron’s Law


  • April 16, 2021
    Introduced in House


  • April 16, 2021
    Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.


  • April 19, 2021
    Referred to the Subcommittee on Health.
Josh Gottheimer

Josh Gottheimer

Democratic Representative

New Jersey

Cosponsors (2)
Don Bacon (Republican)Fred Upton (Republican)

Ways and Means Committee, Health Subcommittee, Energy and Commerce Committee

Taxation

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Business expensesCongressional oversightDrug safety, medical device, and laboratory regulationDrug therapyGovernment studies and investigationsIncome tax creditsMedical researchMedical tests and diagnostic methodsResearch and development